"Bortezomib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
Descriptor ID |
D000069286
|
MeSH Number(s) |
D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bortezomib".
Below are MeSH descriptors whose meaning is more specific than "Bortezomib".
This graph shows the total number of publications written about "Bortezomib" by people in this website by year, and whether "Bortezomib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 3 | 3 |
2003 | 0 | 10 | 10 |
2004 | 0 | 12 | 12 |
2005 | 0 | 17 | 17 |
2006 | 0 | 23 | 23 |
2007 | 0 | 15 | 15 |
2008 | 0 | 11 | 11 |
2009 | 0 | 13 | 13 |
2010 | 0 | 14 | 14 |
2011 | 0 | 23 | 23 |
2012 | 0 | 20 | 20 |
2013 | 0 | 18 | 18 |
2014 | 1 | 20 | 21 |
2015 | 3 | 20 | 23 |
2016 | 5 | 4 | 9 |
2017 | 7 | 5 | 12 |
2018 | 3 | 7 | 10 |
2019 | 3 | 6 | 9 |
2020 | 5 | 6 | 11 |
2021 | 2 | 7 | 9 |
2022 | 0 | 5 | 5 |
2023 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bortezomib" by people in Profiles.
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
-
Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109.
-
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023 09; 61:101100.
-
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 07 15; 129(14):2179-2191.
-
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. Blood Cancer J. 2022 11 29; 12(11):162.
-
Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343.
-
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS One. 2022; 17(7):e0270854.